Raymond James & Associates Ascendis Pharma A/S Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Raymond James & Associates holds 3,601 shares of ASND stock, worth $588,115. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,601
Previous 4,135
12.91%
Holding current value
$588,115
Previous $563,000
4.62%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ASND
# of Institutions
272Shares Held
61.7MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.68 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$895 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$852 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$733 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$695 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $9.11B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...